NHLBI Catalyze funds early research to find and validate drug therapies for heart, lung, blood, and sleep disorders, preparing them for further development.
NHLBI Catalyze program supports early-stage research to identify and characterize small molecule, biologic, and combination product therapeutic candidates for heart, lung, blood, and sleep (HLBS) disorders.
Therapeutic Catalyst supports academic researchers in early drug discovery, funding target identification, validation and early antibody or small molecule development to advance treatments for adult cancers.
Childhood Cancer Therapeutic Catalyst supports academic researchers in collaborative early drug discovery to advance novel therapeutics for children and young people with cancer.
The Lawrence and Isabel Barnett Drug Development Program supports academic and industry investigators conducting preclinical studies of new or repurposed ALS therapies to advance them toward clinical testing.